Regulatory identification of BPA as an endocrine disruptor: Context and methodology.
Authors of this article are:
Beausoleil C, Emond C, Cravedi JP, Antignac JP, Applanat M, Appenzeller BR, Beaudouin R, Belzunces LP, Canivenc-Lavier MC, Chevalier N0, Chevrier C, Elefant E, Eustache F, Habert R, Kolf-Clauw M, Le Magueresse-Battistoni B, Mhaouty-Kodja S, Minier C, Multigner L, Schroeder H, Thonneau P0, Viguié C, Pouzaud F, Ormsby JN, Rousselle C, Verines-Jouin L, Pasquier E, Michel C.
A summary of the article is shown below:
BPA is one of the most investigated substances for its endocrine disruptor (ED) properties and it is at the same time in the center of many ED-related controversies. The analysis on how BPA fits to the regulatory identification as an ED is a challenge in terms of methodology. It is also a great opportunity to test the regulatory framework with a uniquely data-rich substance and learn valuable lessons for future cases. From this extensive database, it was considered important to engage in a detailed analysis so as to provide specific and strong evidences of ED while reflecting accurately the complexity of the response as well the multiplicity of adverse effects. An appropriate delineation of the scope of the analysis was therefore critical. Four effects namely, alterations of estrous cyclicity, mammary gland development, brain development and memory function, and metabolism, were considered to provide solid evidence of ED-mediated effects of BPA.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as:
Bisphenol A;ED;Endocrine disruption;REACh;SVHC;Substance of very high concern
Categories: Science News